The combination of anti-CTLA4 with anti-PD1/PDL1 antibodies enhances antitumor activity early at sites of T-cell activation and in the tumor microenvironment through effector T-cell responses; moreover, it improved the ratios of effector to regulatory T cells and myeloid-derived suppressor cells in preclinical melanoma model, suggesting an overall enhancement of antitumor immunity [65,66,67]. This evidence concerns the gene CD274 and neoplasm.